Published in BMC Bioinformatics on January 07, 2010
Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet (2014) 2.91
Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet (2014) 1.60
Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med (2016) 1.35
Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med (2014) 1.31
Utilizing protein structure to identify non-random somatic mutations. BMC Bioinformatics (2013) 0.96
A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations. BMC Bioinformatics (2014) 0.91
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. Mol Cancer (2011) 0.87
Incorporating molecular and functional context into the analysis and prioritization of human variants associated with cancer. J Am Med Inform Assoc (2012) 0.84
A spatial simulation approach to account for protein structure when identifying non-random somatic mutations. BMC Bioinformatics (2014) 0.83
Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure. Cancer Res (2016) 0.82
Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. Neurol Genet (2016) 0.75
Leveraging protein quaternary structure to identify oncogenic driver mutations. BMC Bioinformatics (2016) 0.75
Computational characterisation of cancer molecular profiles derived using next generation sequencing. Contemp Oncol (Pozn) (2015) 0.75
Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine. BMC Genomics (2016) 0.75
Comparison of algorithms for the detection of cancer drivers at subgene resolution. Nat Methods (2017) 0.75
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
p53 mutations in human cancers. Science (1991) 31.96
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Cancer genes and the pathways they control. Nat Med (2004) 24.22
The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics (2006) 5.56
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol (2006) 4.47
Genetic instability and darwinian selection in tumours. Trends Cell Biol (1999) 4.12
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol (2007) 3.86
LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci (2006) 3.58
The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model. Proc Natl Acad Sci U S A (1990) 3.56
Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Natl Acad Sci U S A (2002) 3.25
The ras gene family and human carcinogenesis. Mutat Res (1988) 3.20
Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res (2007) 2.57
Likelihood models of somatic mutation and codon substitution in cancer genes. Genetics (2003) 2.46
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Methylation, mutation and cancer. Bioessays (1992) 2.11
Prediction of cancer driver mutations in protein kinases. Cancer Res (2008) 1.59
Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. Biochem Biophys Res Commun (2002) 1.26
Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene. Oncogene (2000) 1.25
Structure of the human p53 core domain in the absence of DNA. Acta Crystallogr D Biol Crystallogr (2007) 1.22
Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. J Biol Chem (2007) 1.02
Rapid detection of positive selection in genes and genomes through variation clusters. Genetics (2007) 0.95
Conserved synteny between the Fugu and human PTEN locus and the evolutionary conservation of vertebrate PTEN function. Oncogene (2001) 0.88
Are Parkinson disease patients protected from some but not all cancers? Neurology (2008) 0.85
Structural assessment of single amino acid mutations: application to TP53 function. Hum Mutat (2006) 0.83
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A (2009) 2.84
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic spindle protein. Hum Mol Genet (2005) 1.88
Shuffling of genes within low-copy repeats on 22q11 (LCR22) by Alu-mediated recombination events during evolution. Genome Res (2003) 1.62
Accelerated evolution of the ASPM gene controlling brain size begins prior to human brain expansion. PLoS Biol (2004) 1.54
tRNA genes protect a reporter gene from epigenetic silencing in mouse cells. Cell Cycle (2011) 1.47
Duplication, coclustering, and selection of human Alu retrotransposons. Proc Natl Acad Sci U S A (2004) 1.45
4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J Med Chem (2006) 1.39
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PLoS One (2012) 1.30
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology (2013) 1.26
Human gamma-satellite DNA maintains open chromatin structure and protects a transgene from epigenetic silencing. Genome Res (2009) 1.22
Complexity and simplicity of ligand-macromolecule interactions: the energy landscape perspective. Curr Opin Struct Biol (2002) 1.18
Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models. Clin Cancer Res (2012) 1.10
A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS One (2012) 1.08
Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). Hum Mutat (2008) 1.07
Simulating disorder-order transitions in molecular recognition of unstructured proteins: where folding meets binding. Proc Natl Acad Sci U S A (2003) 1.06
Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. Genome Res (2005) 1.04
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther (2012) 1.04
Evolutionary diversification of SPANX-N sperm protein gene structure and expression. PLoS One (2007) 1.02
Identification of sequence motifs at the breakpoint junctions in three t(1;9)(p36.3;q34) and delineation of mechanisms involved in generating balanced translocations. Hum Genet (2006) 0.99
Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J Pharmacol Exp Ther (2007) 0.97
Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871). Mol Cancer Ther (2013) 0.93
Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics. J Mol Biol (2004) 0.92
P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Mod Pathol (2010) 0.89
Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. Bioorg Med Chem Lett (2009) 0.88
Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry. Protein Sci (2010) 0.88
Targeting the unactivated conformations of protein kinases for small molecule drug discovery. Expert Opin Drug Discov (2008) 0.86
Computational detection of the binding-site hot spot at the remodeled human growth hormone-receptor interface. Proteins (2003) 0.85
Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases. Eur J Med Chem (2007) 0.84
Prediction of specificity-determining residues for small-molecule kinase inhibitors. BMC Bioinformatics (2008) 0.82
The design, annotation, and application of a kinase-targeted library. Methods Mol Biol (2011) 0.80
Antisense inhibition of 11betahydroxysteroid dehydrogenase type 1 improves diabetes in a novel cortisone-induced diabetic KK mouse model. Biochem Biophys Res Commun (2007) 0.78
Kinase inhibition that hinges on halogen bonds. Chem Biol (2011) 0.78
Hierarchy of simulation models in predicting structure and energetics of the Src SH2 domain binding to tyrosyl phosphopeptides. J Med Chem (2002) 0.78
Identification and characterization of a novel and functional murine Pin1 isoform. Biochem Biophys Res Commun (2007) 0.77
Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models. PLoS One (2013) 0.77
Scaffold mining of kinase hinge binders in crystal structure database. J Comput Aided Mol Des (2013) 0.77
Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1). Bioorg Med Chem (2002) 0.76
Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families. Genes Chromosomes Cancer (2012) 0.76
Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding. BMC Genomics (2012) 0.75
Structure-based and property-compliant library design of 11β-HSD1 adamantyl amide inhibitors. Methods Mol Biol (2011) 0.75